Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study

NCT02559960 is registered in ClinicalTrials.gov with Zhong Wang as lead sponsor.

NCT NCT02559960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02559960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Lead sponsor
Zhong Wang
Phase
Observational
Overall status
Suspended
Start date
September 30, 2015
Completion date
December 31, 2021
Enrollment
20,000 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

adverse drug event, adverse drug reaction, anaphylactic reaction, chinese medicine